Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 7/20 | 0.42 |
| ▸ | PSEN1 | P49768 | 10/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 10/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 10/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 10/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 10/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 10/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1360575 | 0.90 | PSEN1 (0.53) | IMPDH2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL16418233 | 0.89 | PSEN1 (0.52) | IMPDH2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1359477 | 0.85 | PSEN1 (0.38) | IMPDH2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL16418224 | 0.79 | PSEN1 (0.64) | IMPDH2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1360967 | 0.77 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1360081 | 0.77 | IMPDH2 (0.50) | IMPDH2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1361046 | 0.77 | TRPV1 (0.35) | POLBLMNATP53MAPTTDP1 | |
| SCHEMBL1360158 | 0.76 | PSEN1 (0.36) | IMPDH2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL16418146 | 0.75 | PSEN1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1360200 | 0.74 | PSEN1 (0.39) | IMPDH2PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281881-A1 | NOVEL SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281881-A1 | NOVEL SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, APH1A | IMPDH2 3553/4885PSEN1 5/4885PSEN2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.